You are currently browsing: triple negative breast cancer
Research into Triple Negative Close to Publication
Triple Negative Breast Cancers (TNBCs) are characterised by high rates of metastases, relapses and chemoresistance. It is now well recognised that breast cancers are not all the same and can be divided into a number of subtypes, which need to be treated differently. When compared to other subtypes of breast cancer, TNBCs often have the […]
Breast Cancer Treatment: Research, Development and Game Changers
Professor Arnie Hill speaks to Sylvia Thompson of The Irish Times about the advances of breast cancer treatment in the past ten years. Prof Arnie Hill, breast cancer surgeon and head of the medical school at The Royal College of Surgeons for Ireland, jokes that many women with breast cancer could almost have a degree […]
Simple test could predict response to anthracycline chemotherapy for patients with ‘triple negative’ breast cancer
Could this be a turning point in breast cancer research? Researchers at Queen’s University Belfast have found a new biomarker that could predict the effectiveness of a common type of chemotherapy for patients with triple negative breast cancer. To read more about this exciting discovery, click the link below: https://breastcancernow.org/news-and-blogs/news/simple-test-could-predict-response-to-anthracycline-chemotherapy-for-patients-with-%E2%80%98triple-negative%E2%80%99-breast-cancer?utm_source=facebooko&utm_medium=social&utm_campaign=news&utm_content=10042019-link&fbclid=IwAR1_8dY2gWwAG8m7h9QBj7wuEy6DY8EKdhw43n5jweYkPP646pReEphtHQs
FDA approves Atezolizumab for Triple-Negative Breast Cancer
The US FDA has granted accelerated approval of a new treatment for triple-negative breast cancer, which is difficult to treat. Further trials are required, but early studies strongly suggest that patients with triple-negative breast cancer benefit from this combination treatment. For further details, click on the link below: https://www.cancer.gov/news-events/cancer-currents-blog/2019/atezolizumab-triple-negative-breast-cancer-fda-approval?fbclid=IwAR00ZVHpsrp2qMMLx1Z9stNVarNL9Hqs_9WcpWrSO4vgYWFYqZKSKtpYepc
